Travere Therapeutics (NASDAQ:TVTX) Share Price Crosses Below 200 Day Moving Average – What’s Next?

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $47.99 and traded as low as $46.90. Travere Therapeutics shares last traded at $46.9940, with a volume of 1,329,568 shares.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Friday, September 18th. Guggenheim lowered their target price on Travere Therapeutics from $89.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $67.00 target price on shares of Travere Therapeutics in a report on Tuesday, September 22nd. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. Finally, Zacks Research upgraded shares of Travere Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $72.55.

Read Our Latest Stock Analysis on Travere Therapeutics

Travere Therapeutics Price Performance

The company has a current ratio of 3.00, a quick ratio of 2.95 and a debt-to-equity ratio of 26.72. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of -36.43 and a beta of 1.11. The company has a 50 day moving average of $54.23 and a 200 day moving average of $47.99.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The firm had revenue of $224.56 million for the quarter, compared to analyst estimates of $195.29 million. During the same period in the prior year, the company earned $0.28 earnings per share. The firm’s quarterly revenue was up 36.2% on a year-over-year basis. Equities research analysts predict that Travere Therapeutics, Inc. will post -0.90 EPS for the current fiscal year.

Insider Activity at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 37,500 shares of Travere Therapeutics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $62.34, for a total value of $2,337,750.00. Following the completion of the sale, the insider owned 105,389 shares in the company, valued at $6,569,950.26. The trade was a 26.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric M. Dube sold 243,735 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $53.82, for a total value of $13,117,817.70. Following the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at $23,297,924.52. The trade was a 36.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,294,029 shares of company stock valued at $79,454,261. Insiders own 4.44% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. S&CO Inc. bought a new position in Travere Therapeutics in the 2nd quarter valued at $3,181,000. Artia Global Partners LP purchased a new position in shares of Travere Therapeutics in the second quarter worth about $19,260,000. Elmind Capital LP purchased a new stake in shares of Travere Therapeutics during the 2nd quarter valued at approximately $16,622,606. Bank of America Corp DE bought a new position in Travere Therapeutics in the 2nd quarter worth approximately $259,527,000. Finally, Insight Wealth Strategies LLC bought a new stake in Travere Therapeutics during the 3rd quarter valued at $5,692,000.

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

See Also

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.